Global Peptide Therapeutics Industry Set to Attain US$106 Billion by 2033, Fueled by a Robust 10.8% CAGR | FMI Inc.

The Global Peptide Therapeutics Industry is poised for exceptional growth, reaching a projected valuation of US$ 38.0 billion in 2023 and an astonishing US$ 106.0 billion by 2033. This remarkable surge is underpinned by a robust compound annual growth rate (CAGR) of 10.8% from 2023 to 2033.

The exponential expansion of the Global Peptide Therapeutics Industry is directly attributed to the myriad advantages these therapies offer. Notably, their consistent efficacy in treating metabolic disorders has been a driving force behind this unprecedented growth, a trend expected to persist over the entire forecast period.

Request a Sample Copy of This Report Now.
https://www.futuremarketinsights.com/reports/sample/rep-gb-1038

Further, peptide therapeutics can be a preferred alternative to small molecule and biological therapeutics. All of these factors have led to an upsurge in research and investments in peptide drug recovery over the last ten years and are expected to bode well for the prospects of the market.

Again, surging incidences of metabolic disorders and high prevalence of cancer propel the demand for investments in research and development activities in the field of peptide therapies. These illnesses are the prime cause of death and disability all over the world. As a result, there a greater demand for the development of peptide therapeutics. Peptide-based drug delivery for cancer cells coupled with enhancements in the next generation therapeutics will presumably supplement the market expansion of peptide therapeutics. In addition to this, there’s a rise in the interest in therapeutic peptide research due to commercial reasons. Thus, it is presumed that peptide drug recovery will play a crucial role in the healthcare industry.

“Heightened application of peptides in the treatment of diabetes and cancer will likely augment the sales of peptide therapeutics in the global market over the forecast period,” says an FMI analyst.  

Key Takeaways:

• The popularity of oral peptide-based drugs to generate attractive market opportunities.
• Peptide-based therapeutics will continue to gain momentum in Cosmeceuticals.
• Government support to aid market growth in North America.
• India will offer various lucrative opportunities to the peptide therapeutics industry.
• Based on the route of administration, the parenteral route segment will continue to gain preference during the assessment period.

Methodology Details Just a Click Away!
https://www.futuremarketinsights.com/request-report-methodology/rep-gb-1038

Competitive Landscape:

Eli Lilly and Company, AstraZeneca plc, Merck & Co., Inc., Ipsen S.A, Novo Nordisk A/S, and Teva Pharmaceutical Industries Ltd., among others are some of the major players in the Global Peptide Therapeutics Industry that are profiled in the full version of the report.

In a moderately competitive market, major players are concentrating on market expansion activities. These organizations are engaging in distribution agreements, white space exploration, and collaborative ventures. The more established businesses are focusing on working with local players in order to expand their production capacities and improve their regional presence.

More Insights into the Global Peptide Therapeutics Industry Report

In its latest report, FMI offers an unbiased analysis of the global peptide therapeutics market, providing historical data from 2014 to 2021 and forecast statistics for 2022 to 2025. To understand the global market potential, growth, and range, the market is segmented based on application (cancer, cardiovascular diseases, central nervous systems, metabolic disorders, infections, hematological disorders, gastrointestinal disorders, dermatology, respiratory disorders, acromegaly, other applications), route of administration (parenteral route of administration, mucosal route of administration, oral route of administration, transdermal route of administration), drug type (branded drugs, generic/ biosimilar drugs), and region.

According to the latest FMI reports, based on region, the peptide therapeutics market in North America is expected to dominate the market over the forecast period. A surge in government investments as well as an increase in industry spending on research and development activities in peptide therapeutics is driving the regional market growth. This market is further supported by the target market expansion in the United States.   Owing to the high prevalence of cancer along with increasing research and development activities, the U.S. peptide therapeutics market is expected to witness impressive growth over the forecast period.

In India, the Global Peptide Therapeutics Industry is anticipated to gain many profitable future prospects. The rising adoption of synthetic peptide drugs in India will likely propel the market growth in this region. Rising incidences of chronic illnesses and an ageing population also contribute to the market growth.

Based on segmentation, based on route of administration, the parenteral route will continue to gain momentum over the forecast period.

Access Exclusive Market Insights – Purchase Now
https://www.futuremarketinsights.com/checkout/1038

Key Segments:

By Application:

• Cancer
• Cardiovascular Diseases
• Central Nervous Systems
• Metabolic Disorders
• Infections
• Hematological Disorders
• Gastrointestinal Disorders
• Dermatology
• Respiratory Disorders
• Acromegaly
• Other Applications

By Route of Administration:

• Parenteral Route of Administration
• Mucosal Route of Administration
• Oral Route of Administration
• Transdermal of Route Administration

By Drug Type:

• Branded Drugs
• Generic/Biosimilar Drugs

Author

Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.

Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.

Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.